SCHEMBL2812487

SCHEMBL2812487

COc1ccc(C2OCc3cc(C#N)ccc32)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.45
MEN1 O00255 5/20 0.45
POLB P06746 3/20 0.45
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
BLM P54132 1/20 0.39
LMNA P02545 2/20 0.39
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
ALDH1A1 P00352 1/20 0.37
CASP1 P29466 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MYB P10242 1/20 0.37
SLC6A4 P31645 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
SNCA P37840 1/20 0.36
KDM1A O60341 3/20 0.36
MAOA P21397 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22043585 0.82 FADS1 (0.40) BLMLMNAALDH1A1SLC6A4
SCHEMBL14199799 0.82 FADS1 (0.40) BLMLMNAALDH1A1SLC6A4
SCHEMBL1686 0.82 FADS1 (0.40) BLMLMNAALDH1A1SLC6A4
SCHEMBL27947259 0.77 CA1 (0.47) CA1CA2CA9CA14LMNA
Oxalic Acid SCHEMBL15154934 0.76 LMNA (0.42) LMNASLC6A4
SCHEMBL14102319 0.74 SLC6A4 (0.49) CA1CA2CA9CA14LMNA
SCHEMBL13967341 0.70 SLC6A4 (0.50) KMT2AMEN1CA1CA2CA9
SCHEMBL16312591 0.69 FADS1 (0.39) BLMLMNAALDH1A1SLC6A4
SCHEMBL23481105 0.69 PNMT (0.41) SLC6A4KDM1AMAOA
SCHEMBL14489506 0.68 KDM1A (0.43) KMT2AMEN1POLBCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242159-B2 1,3-dihydro-5-isobenzofurancarbonitrile derivatives and pharmaceutical composition thereof for the treatment of premature ejaculation DONG-A PHARMACEUTICAL. CO., LTD (KR) 2012-08-14 US disclosed
US-20100240725-A1 NOVEL 1,3-DIHYDRO-5-ISOBENZOFURANCARBONITRILE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF PREMATURE EJACULATION DONG-A PHARMACEUTICAL. CO., LTD (KR) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240725-A1 NOVEL 1,3-DIHYDRO-5-ISOBENZOFURANCARBONITRILE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF PREMATURE EJACULATION SLC18A2, SLC18A1, SLC6A4 KMT2A 4753/4885MEN1 3039/4885POLB 2308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.